Sage Journals: Discover world-class research

Open access

Research article

First published 2022-7

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study

Gavin Giovannoni, Barry A Singer, Delphine Issard [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2018

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod

Lara Diem, Krassen Nedeltchev, Timo Kahles [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2018

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis

Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2021-11

Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

Tomas Uher, Eva Kubala Havrdova, Pascal Benkert [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2024-6

Extended interval dosing with ocrelizumab in multiple sclerosis

Frederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2021-12

Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation

Graham Cooper, Claudia Chien, Hanna Zimmermann [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2020

Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients

Mario Stampanoni Bassi, Jelena Drulovic, Tatjana Pekmezovic [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2023-1

Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

Ricardo Alonso, Magdalena Casas, Luciana Lazaro [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2017-2

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Tomas Uher, Eva Havrdova, Lukas Sobisek [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2016-9

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Ludwig Kappos, Nicola De Stefano, Mark S Freedman [...]

Multiple Sclerosis Journal

Search results